Cancer Gene Therapy

Phase I/II trial results look good so far in breast cancer patients

Published in Gene Therapy Weekly, July 31st, 2003

Oxford BioMedica (LSE:OXB) announced encouraging results from its ongoing, small, Phase I/II trial with MetXia in breast cancer patients.

The company also announced regulatory progress towards starting a Phase I/II trial with MetXia in pancreatic cancer.

MetXia is Oxford BioMedica's leading gene-based cancer therapeutic. The product is based on a highly engineered retrovirus gene delivery system expressing a specific human cytochrome P450 gene. MetXia converts the tumor into a 'drug factory,' enabling increased local production of the antitumor, cytotoxic derivative of the prodrug cyclophosphamide. MetXia is potentially useful in the treatment of all...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2003-07-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry